4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 55.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 296,199 shares of the company’s stock after selling 367,458 shares during the period. Assenagon Asset Management S.A.’s holdings in 4D Molecular Therapeutics were worth $2,221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Armistice Capital LLC increased its holdings in 4D Molecular Therapeutics by 265.3% in the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock worth $9,524,000 after acquiring an additional 796,000 shares in the last quarter. Wexford Capital LP purchased a new position in 4D Molecular Therapeutics during the third quarter valued at $41,000. Prelude Capital Management LLC grew its position in shares of 4D Molecular Therapeutics by 11.1% in the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock valued at $200,000 after purchasing an additional 2,300 shares during the period. Parkman Healthcare Partners LLC acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at about $1,738,000. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of 4D Molecular Therapeutics during the third quarter worth about $143,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Down 8.1%

4D Molecular Therapeutics stock opened at $8.57 on Tuesday. The company has a fifty day simple moving average of $8.95 and a 200-day simple moving average of $9.24. The firm has a market capitalization of $437.50 million, a price-to-earnings ratio of -3.54 and a beta of 2.99. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.23 and a 52-week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.96. The firm had revenue of $85.09 million for the quarter, compared to the consensus estimate of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. On average, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

FDMT has been the subject of several research analyst reports. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price target for the company. Jefferies Financial Group reiterated a “buy” rating and issued a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Finally, Royal Bank Of Canada raised their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $31.25.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.